Literature DB >> 2031693

Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature.

J Altés1, A Salas, M Riera, M Udina, A Galmés, J Balanzat, A Ballesteros, J Buades, F Salvá, C Villalonga.   

Abstract

Visceral leishmaniasis (VL) is considered an opportunistic infection in immunocompromised patients. We review the clinical, laboratory, and therapeutic data in 63 patients (eight new cases and 55 cases reported in the literature) with Mediterranean VL (kala azar) and HIV-1 infection to determine whether VL should be considered an opportunistic infection in HIV-infected adults. We conclude that: (1) in areas where both leishmaniasis and HIV-1 infection are endemic, VL may be more frequent among HIV-infected adults; (2) in HIV-infected patients, the clinical picture did not differ significantly from classical kala azar, although it often ran a recurrent course, with resistance to antimonial therapy. We propose the inclusion of VL in the IVC-2 subgroup of the Centers for Disease Control (CDC) clinical classification of HIV-1 infection while prospective and larger studies further define whether there are clinical presentations that could justify adding VL to the list of opportunistic infections indicative of AIDS.

Entities:  

Mesh:

Year:  1991        PMID: 2031693

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  23 in total

1.  Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model.

Authors:  M Paul; R Durand; H Fessi; D Rivollet; R Houin; A Astier; M Deniau
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  Visceral leishmaniasis in a child with HIV-1 infection.

Authors:  A Guarino; A Castaldo; L Di Martino; A Rubino; G B Gaeta; L Gradoni
Journal:  Eur J Pediatr       Date:  1994-04       Impact factor: 3.183

Review 4.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  PCR and in vitro cultivation for detection of Leishmania spp. in diagnostic samples from humans and dogs.

Authors:  A Mathis; P Deplazes
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

6.  Injecting drug use as risk factor for visceral leishmaniasis in AIDS patients.

Authors:  C Amela; D López-Gay; J C Alberdi; J Castilla
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

7.  Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.

Authors:  H W Murray; J Hariprashad; R E Fichtl
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient.

Authors:  H Albrecht; H J Stellbrink; G Gross; B Berg; U Helmchen; H Mensing
Journal:  Clin Investig       Date:  1994-12

Review 9.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

10.  Effect of chlorpyrifos on healing of cutaneous leishmaniasis lesions after treatment with Pentostam(®).

Authors:  Asya N Al-Dawood; Ramadan A Al-Ghazal; May H Al-Jaser; Galila M Khalil
Journal:  Saudi J Biol Sci       Date:  2009-07       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.